Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven s lead investigational drug from its Molecular Degrader of Extracellular.
NEW HAVEN, Conn., April 22, 2024 /PRNewswire/ Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses.